Products - Eye conditions | Topic | NICE

Showing 10 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Diabetic retinopathy
Status:
In development
Programme:
NICE guideline
Expected publication date:
2 February 2024
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
1 May 2024
Pegcetacoplan for treating geographic atrophy [ID4041]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
12 June 2024
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
19 June 2024
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder [ID5105]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Faricimab for treating macular oedema caused by retinal vein occlusion ID6197
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous treatment (Review of TA613) [ID6307]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC